Daratumumab

Category: Cancer



Daratumumab Overview

Daratumumab (trade name Darzalex) is an anti-cancer drug. It binds to CD38,[1] which multiple myeloma cells overexpress.[2] Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.[3] Daratumumab was given breakthrough therapy drug status in 2013 for multiple myeloma. I...

Read more Daratumumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daratumumab

Recent Daratumumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Daratumumab
  • Injection: 100mg/5ml, 400mg/20ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Daratumumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 17 August 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA